Suven Life Sciences Limited — Others, 29-10-2024: Statement of deviation(s) or variation(s) under Reg. 32

Suven Life Sciences Limited reported that for the quarter ended September 30, 2024, there were no deviations or variations in the use of funds raised through their Rights Issue. A total of ₹399.80 crores was raised, of which funds allocated for pharmaceutical research and repayment of inter-corporate deposits were fully utilized. However, ₹60.42 crores remain unutilized for general corporate purposes. The monitoring agency for these funds is CRISIL Ratings Limited.